Compare NEON & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NEON | SCYX |
|---|---|---|
| Founded | 1997 | 1999 |
| Country | Sweden | United States |
| Employees | 43 | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.9M | 32.6M |
| IPO Year | 1994 | 2014 |
| Metric | NEON | SCYX |
|---|---|---|
| Price | $1.65 | $0.93 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $6.00 | $3.00 |
| AVG Volume (30 Days) | 96.7K | ★ 313.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 37.88 | ★ 61.36 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,108,000.00 | $257,000.00 |
| Revenue This Year | N/A | $90.24 |
| Revenue Next Year | $43.34 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.50 | $0.57 |
| 52 Week High | $29.90 | $1.29 |
| Indicator | NEON | SCYX |
|---|---|---|
| Relative Strength Index (RSI) | 44.20 | 66.73 |
| Support Level | N/A | $0.68 |
| Resistance Level | $2.04 | $1.29 |
| Average True Range (ATR) | 0.09 | 0.06 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 34.44 | 83.09 |
Neonode Inc provides optical sensing solutions for contactless touch, and gesture sensing and also provides software solutions for machine perception that feature machine learning algorithms to detect and track persons and objects in video streams from cameras and other types of imagers. It markets and sells its solutions to customers in many different markets and segments including, office equipment, automotive, industrial automation, medical, military, and avionics. The company geographically operates in the United States, Japan, South Korea, Germany, Sweden, China, and other regions. A majority of its revenue is generated from Japan.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.